Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Related Articles by Review for PubMed (Select 11289126)

1.

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.

Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ.

Cancer Res. 2001 Mar 15;61(6):2533-6.

2.

Circulating angiogenesis regulators in cancer patients.

Kuroi K, Toi M.

Int J Biol Markers. 2001 Jan-Mar;16(1):5-26. Review.

PMID:
11288955
3.

Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.

Autorino R, Di Lorenzo G, Damiano R, De Placido S, D'Armiento M.

Urol Int. 2003;70(1):1-14. Review.

PMID:
12566808
4.

Angiogenesis in human gliomas: prognostic and therapeutic implications.

Johnson JP, Bruce JN.

EXS. 1997;79:29-46. Review. No abstract available.

PMID:
9002219
5.

VEGF and prostatic cancer: a systematic review.

Botelho F, Pina F, Lunet N.

Eur J Cancer Prev. 2010 Sep;19(5):385-92. doi: 10.1097/CEJ.0b013e32833b48e1. Review.

PMID:
20502342
6.

Therapy for hormone-resistant prostate cancer: no longer a myth.

Petrylak DP, Abi-Rashid B.

Cancer Treat Res. 1996;88:211-8. Review.

PMID:
9239482
7.

Urine markers in monitoring for prostate cancer.

Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):12-9. doi: 10.1038/pcan.2009.31. Epub 2009 Aug 4. Review.

PMID:
19652665
8.
9.

Angiogenic factors as tumor markers.

Nguyen M.

Invest New Drugs. 1997;15(1):29-37. Review.

PMID:
9195287
10.

Therapeutic alternatives for hormone-refractory prostatic cancer.

Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM.

Semin Urol. 1992 Feb;10(1):55-64. Review.

PMID:
1373515
11.

[Basic fibroblast growth factor (bFGF/FGF-2) in urine].

Ishiwata T, Naito Z.

Nihon Rinsho. 2005 Aug;63 Suppl 8:768-70. Review. Japanese. No abstract available.

PMID:
16149636
12.

Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.

LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Myers CE.

Urol Clin North Am. 1991 Feb;18(1):123-9. Review.

PMID:
1992566
13.

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.

Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.

Mol Cancer Ther. 2009 Sep;8(9):2496-508. doi: 10.1158/1535-7163.MCT-09-0302. Epub 2009 Sep 15. Review.

14.

[Basic fibroblast growth factor in urine].

Ishiwata T, Asano G.

Nihon Rinsho. 1999 Dec;57 Suppl:589-92. Review. Japanese. No abstract available.

PMID:
10778199
15.

MET and VEGF: synergistic targets in castration-resistant prostate cancer.

Aftab DT, McDonald DM.

Clin Transl Oncol. 2011 Oct;13(10):703-9. doi: 10.1007/s12094-011-0719-5. Review.

16.

Suramin, a novel antitumor compound.

La Rocca RV, Stein CA, Danesi R, Myers CE.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):893-8. Review.

PMID:
2285603
17.

Differentiating agents and nontoxic therapies.

Myers CE.

Urol Clin North Am. 1999 May;26(2):341-51, ix. Review.

PMID:
10361557
18.

Prognostic and predictive markers in hematologic neoplasms. A review.

Gorczyca W.

Pol J Pathol. 2011 Dec;62(4):189-205. Review. No abstract available.

PMID:
22246905
19.

Suramin.

Eisenberger MA, Sinibaldi V, Reyno L.

Cancer Pract. 1995 May-Jun;3(3):187-9. Review. No abstract available.

PMID:
7599677
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk